

CHEMICAL HERITAGE FOUNDATION

PHILLIP D. ZAMORE

Pew Scholars Program in the Biomedical Sciences

Transcript of an Interview
Conducted by

Karen A. Frenkel

at

University of Massachusetts Medical School
Worcester, Massachusetts

on

20 and 21 December 2007
(With Subsequent Corrections and Additions)



Phillip D. Zamore

ACKNOWLEDGEMENT

This oral history is part of a series supported by a grant from the Pew Charitable Trusts based on the Pew Scholars Program in the Biomedical Sciences. This collection is an important resource for the history of biomedicine, recording the life and careers of young, distinguished biomedical scientists and of Pew Scholars Program in the Biomedical Sciences Advisory Committee members.

This oral history is made possible through the generosity of



CHEMICAL HERITAGE FOUNDATION
Oral History Program
FINAL RELEASE FORM

This document contains my understanding and agreement with the Chemical Heritage Foundation with respect to my participation in the audio-recorded interview conducted by Karen A Frenkel on 20 and 21 December 2007. I have read the transcript supplied by Chemical Heritage Foundation.

1. The audio recording, corrected transcript, photographs, and memorabilia (collectively called the "Work") will be maintained by the Chemical Heritage Foundation and made available in accordance with general policies for research and other scholarly purposes.
2. I hereby grant, assign, and transfer to the Chemical Heritage Foundation all right, title, and interest in the Work, including the literary rights and the copyright, except that I shall retain the right to copy, use, and publish the Work in part or in full until my death.
3. The manuscript may be read and the audio recording(s) heard by scholars approved by the Chemical Heritage Foundation subject to the restrictions listed below. The scholar pledges not to quote from, cite, or reproduce by any means this material except with the written permission of the Chemical Heritage Foundation.
4. I wish to place the conditions that I have checked below upon the use of this interview. I understand that the Chemical Heritage Foundation will enforce my wishes until the time of my death, when any restrictions will be removed.

Please check one:

a. _____

No restrictions for access.

NOTE: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to obtain permission from Chemical Heritage Foundation, Philadelphia, Pennsylvania.

b. _____

Semi-restricted access. (May view the Work. My permission required to quote, cite, or reproduce.)

c. _____

Restricted access. (My permission required to view the Work, quote, cite, or reproduce.)

This constitutes my entire and complete understanding.

(Signature)

Phillip D. Zamore


(Date)

1 April 2008

This interview has been designated as **Semi Restricted Access**.

One may view the oral history with the permission of CHF.
However, the permission of the interviewee is required to quote from, cite, or reproduce the oral history.

Please contact CHF to request permission.



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries in shaping society.

Phillip D. Zamore

1963 Born in Brooklyn, New York on 29 November

Education

1986 A.B., Biochemistry and Molecular Biology, Harvard University
1992 Ph.D., Biochemistry and Molecular Biology, Harvard University
1992 Advanced *Drosophila* Gene Course, Cold Spring Harbor, New York

Professional Experience

The Whitehead Institute for Biomedical Research, Cambridge, Massachusetts

1993-1999 Postdoctoral research with Ruth Lehmann
1998-1999 Postdoctoral research jointly with David P. Bartel
1996-1999 Postdoctoral research jointly with James R. Williamson

University of Massachusetts Medical School, Worcester, Massachusetts

1999-2002 Assistant Professor, Department of Biochemistry and Molecular Pharmacology
2002-2005 Associate Professor, Department of Biochemistry and Molecular Pharmacology
2004-2005 Associate Professor with tenure, Department of Biochemistry and Molecular Pharmacology
2005-present Professor, Department of Biochemistry and Molecular Pharmacology
2005-present Gretchen Stone Cook Professor of Biomedical Sciences, Department of Biochemistry and Molecular Pharmacology

Honors

2007 RNAi Innovator Award, "RNAi Meeting," Boston, Massachusetts
2002-2007 W.M. Keck Foundation Young Scholar in Medical Research
2000-2004 Pew Scholar in the Biomedical Sciences
1997-1999 Charles H. Hood Postdoctoral Fellowship
1993-2006 Life Sciences Research Foundation Postdoctoral Fellowship
1987-1990 National Science Foundation Pre-Doctoral Fellowship

ABSTRACT

Philip D. Zamore's oral history begins with a discussion of his childhood in New York City and Long Island. Explaining his family's emphasis on education and the influence of his father, Zamore detailed his father's illness and death while Zamore attended Harvard University. As an undergraduate at Harvard Zamore developed his interest in science and decided to focus on molecular biology. He spent time in several laboratories including one summer at The Rockefeller University with Sid Strickland and Michael W. Young, though the majority of his laboratory experience was at Massachusetts General Hospital with John H. Hartwig. Staying at Harvard for a semester after graduating to work as a laboratory technician with Michael R. Green, Zamore decided to conduct his graduate research there as well. He moved with Green from Harvard to the University of Massachusetts, Worcester, where his work on snRNP flourished. Subsequently Zamore undertook postdoctoral research with Ruth Lehmann at the Whitehead Institute for Biological Studies at MIT and he collaborated with the laboratories of James R. Williamson and David P. Bartel after Lehmann moved to the Skirball Institute of Biomolecular Medicine at New York University. After his postdoctoral studies, but before moving to his Principal Investigator position at the University of Massachusetts, Zamore began working in the emerging field of RNAi. He detailed his experiences with RNAi and his early work running his own laboratory including the receipt of the Pew Scholars Program in the Biomedical Sciences Award. Throughout the interview Zamore discussed the importance of writing and publishing and his relationship with his students, as well as balancing his family life with his career. He also compared government funding to private funding, and criticized the U.S. government for not sponsoring riskier science. Zamore explained his experiences in starting the biotech firm Alnylam Pharmaceuticals and concluded his oral history interview with a discussion of trends in biomedical science, RNA research, and globalization.

INTERVIEWER

Karen A. Frenkel is a writer, documentary producer, and author specializing in science and technology and their impacts on society. She wrote *Robots: Machines in Man's Image* (Harmony 1985) with Isaac Asimov. Her articles have appeared in many magazines and newspapers including *The New York Times*, *CyberTimes*, *Business Week*, *Communications Magazine*, *Discover*, *Forbes*, *New Media*, *Personal Computing*, *Scientific American*, *Scientific American MIND*, *The Village Voice*, and *Technology Review*. Ms. Frenkel's award-winning documentary films, *Net Learning* and *Minerva's Machine: Women and Computing* aired on Public Television. She has been an interviewer for Columbia University's Oral History Research Center's 9/11 Narrative and Memory project, The National Press Foundation's Oral History of Women in Journalism, and the International Psychoanalytic Institute for Training and Research's Oral History. Professional memberships include: The Authors Guild, National Association of Science Writers, Writer's Guild of America East, and New York Women in Film and Television: Past Member of the Board and Director of Programming. Her website is www.Karenafrenkel.com.

TABLE OF CONTENTS

Childhood and Early Education	1
Growing up on Long Island. Father's illness and death. Education prized in family. Summer science courses at Columbia University and Roswell Park Cancer Institute. Interests in graphic design and journalism. Importance of family.	
Undergraduate Education	10
Harvard University. Molecular Biology course. Developing interest in obtaining a Ph.D. Laboratory experiences with John Hartwig and David Beck. Summer Research at Rockefeller University with Sid Strickland and Michael [W.] Young.	
Graduate Education	22
Harvard University. Technician for Michael R. Green. Moving from Harvard University to the University of Massachusetts, Worcester. Side project on snRNA. Successful research on snRNPs.	
Postdoctoral Research	35
Developmental RNA research with Ruth Lehmann at the Whitehead Institute for Biomedical Research. Her move to the Skirball Institute of Biomolecular Medicine at New York University. Jointly advised by James R. Williamson, David P. Bartel, and Lehmann. Different laboratory styles.	
Principal Investigator	38
Choosing position at the University of Massachusetts, Worcester. Beginning of RNAi research. Gene silencing. Writing papers.	
Pew Scholars Program in the Biomedical Sciences	50
Prestige of other scholars. Established fields versus RNAi research. Annual Meetings. Sense of community. Scientific research and the continuity of science.	
The Scientific Life	55
Obligations to students. Writing and publishing papers. Scientific competition. Styles of scientific writing.	
Funding	62
Keck Fellowship. Grants as confidence builders. Fairness of NIH R01 system. Briefly without external funding. NIH grant scores and percentiles. Flawed general funding situation. Publishing versus speaking. RNAi research. Risk. Biotech.	

Private and Public Science	77
Alnylam Pharmaceuticals. Distinction between funding for company and funding for laboratory. Collaboration. Patents and scientific culture. Basic science. Pew Scholars Program in the Biomedical Sciences. Department of Homeland Security.	
Family Life	90
Balancing family and research. Children and postdoctoral research. Campaign for improved day care. Nobel Prize Talks in Sweden.	
Trends in the Scientific Community	99
Biomedical trends and RNA research. Publishing. Increased scientific specialization.	
Biomedical Science and the Public	102
Politics and funding. Investment in a scientific future. Insults to scientific process and thought. NIH. Translational research.	
Scientists and Science	105
Time management. Howard Hughes Medical Institute. Public understanding of science. Globalization and science. Restrictions on science.	
Index	120

INDEX

A

Actin, 17
Africa, 110
AIDS [Acquired Immune Deficiency Syndrome], 104
Alnylam Pharmaceuticals, 77, 83, 93
Aronin, Neal, 82
ATP [adenosine triphosphate], 76

B

Bach, Johann Sebastian, 88
Baghdad, Iraq, 103
Bank of America, 79
Barnard College, 5
Bartel, David P., 32, 33, 35, 42, 43, 44, 45, 46, 77
Bayh-Dole Act, 86, 87
Begg, David A., 18
Biology, 3, 6, 8, 11, 20, 21, 29, 31, 34, 41, 55, 74, 76, 82, 90, 100, 102, 105, 107
 advanced placement, 8
 biochemistry, 11, 15, 20, 40, 41, 42
 biophysics, 17
 developmental biology, 20, 33
 genetics, 102
 molecular biology, 6, 11, 12, 20, 21, 22, 27, 29, 102, 105, 107
 organismal biology, 20
 structural biology, 102
Biotech, 5, 31, 79, 81, 86, 87, 94
Biotin, 21
Blacklow, Stephen C., 69
Blobel, Günter, 20
Boston, Massachusetts, 9, 18, 38, 91, 92, 93, 94, 95
Brigham and Women's Hospital, 16
Burberry, 114
Bush, George W., 104, 105, 116

C

C. elegans, 85
calcimine, 95
California, 116
Caltech [California Institute of Technology], 38, 39, 41, 55
Cambridge, Massachusetts, 11, 17, 29, 31, 94
Camus, Albert, 9
Cancer, 2, 83, 84, 89, 90, 102
Caribbean, 51, 52
Carruthers, Anthony J., 51
Carthew, Richard W., 43
CBS News, 44, 111
Cell, 30, 47, 52
Charlestown, Massachusetts, 94, 95
Chemistry, 3, 31, 32, 35, 102, 107
 advanced placement, 8
Chicago, Illinois, 51
China, 61, 103, 113, 114
Circadian Rhythm, 19
Clinton, William J., 64
CO₂, 32
Cold Spring Harbor Laboratory, 12, 46
Colinvaux, Catherine M., 44
Colinvaux, Paul, 72
Collaborations, 31, 41, 82, 83, 115
Columbia University, 1, 4, 5, 8, 20, 55
 Columbia Law School, 1
Costa Rica, 53

D

Davis, Roger J., 41
DeGrado, William F., 21
Democratic Party, 2
Department of Defense, 90
Department of Homeland Security, 90
DNA, 6, 43, 105
Drosophila, 41, 45

E

E. I. du Pont de Nemours and Company, 21
Ebola, 80
ENCODE Project, 105
Endocrinology, 82
England, 3
ENZO Biomedicals, 5
Enzymes, 17, 21, 70

F

Fire Island, New York, 8, 9
Fire, Andrew Z., 43, 45, 97, 99
France, 103, 113, 117
Fruit Flies. *See Drosophila*
Funding, 64, 66, 67, 68, 70, 77, 80, 86, 89,
90, 100, 103, 104, 105, 110, 111, 113,
114, 117

G

Garden City, New York, 1
Garrett, Laurie, 54
Genes
 exons, 26
 gene silencing, 44, 45, 70, 90
 introns, 26
Genes & Development, 46
Germany, 43, 97, 103, 113
Golden Fleece Awards, 88
Grants, 16, 49, 61, 63, 64, 65, 66, 67, 70,
73, 89, 90, 105, 106, 107, 117
Great Depression, 1
Green, Michael R., 19, 21, 22, 23, 26, 28,
29, 31, 35, 40, 41, 43
Grodzicker, Terri, 46

H

Hamiltonian Operators, 32
Hannon, Gregory J., 44, 47, 48, 113
Harrison, Stephen C., 29
Hartwig, John H., 16, 18, 22
Harvard University, 4, 10, 11, 14, 15, 17,
18, 20, 21, 24, 28, 29, 43, 50, 58, 118
Hepatitis C, 84
Home Depot, 94

Howard Hughes Medical Institute, 110
Huntington's Disease, 82, 83

I

IBM [International Business Machines], 86
India, 103
Interferon, 7
Iran, 113
Iraq, 90, 103, 104, 105, 114
Isis Pharmaceuticals Inc., 84

J

Japan, 61, 113, 114
Judaism, 10
Judson, Horace Freeland, 12

K

Kennedy, John F., 112
Kentucky, 114, 118
Keystone Symposia, 102
Kim, Peter S., 31, 81
Kim, V. Narry, 70
Kleckner, Nancy E., 22
Knowles, Jeremy R., 21

L

Lego, 4, 76
Lehmann, Ruth, 30, 31, 32, 33, 34, 35, 37,
42, 43, 52
Lieberman, Judy, 84
Lincoln, Abraham, 72
Long Island, New York, 1, 8, 11
Lymph Nodes, 2

M

Massachusetts General Hospital, 16, 17
Matranga, Christian B., 71
Matthews, C. Robert, 41
Melanoma, 2
Mello, Craig C., 4, 43, 45, 82, 97, 99
Microsoft, 86
Minneapolis, Minnesota, 39
MIT [Massachusetts Institute of
Technology], 27, 31, 32, 40, 42, 50, 118

Molecular Medicine, 40
Mooney, Chris, 104
Moore, Melissa J., 57
Morgan, Thomas H., 55
Mozart, Wolfgang Amadeus, 88

N

National Cancer Institute, 90
Nature, 46, 47, 72, 111
Neuroscience, 113
Nevada, 112
New York State Bar Association, 2
New York Stock Exchange, 104
New York Times, 81
New York, New York, 1, 2, 3, 4, 7, 8, 9, 11,
13, 18, 19, 32, 33
Brooklyn, 1
East Flatbush, 13
NIH [National Institutes of Health], 59, 64,
70, 86, 88, 89, 90, 103, 104, 105
NMR [Nuclear Magnetic Resonance], 31,
32
Nobel Committee, 97, 99
Nobel Prize, 97, 99
Novartis, 79
NPR [National Public Radio], 112
NSA [National Security Agency], 43
NYU [New York University], 30

O

Office of Naval Research, 89
Operon, 12
Outward Bound, 53

P

Page, David C., 115
Pandemic Flu, 80
Pasteur, Louis, 73
Patents, 85, 86, 87
Pew Charitable Trusts
annual meeting, 51, 52, 53, 54
Pew Scholars Program in the Biomedical
Sciences, 1, 30, 43, 44, 51, 52, 53, 63,
69, 70, 88, 92, 106, 114, 117

Pfizer, 76
Pharmacology, 41, 42
Phillips Exeter Academy, 8, 9, 58
Ploegh, Hidde L., 118
*PNAS [Proceedings of the National Academy
of Sciences]*, 102
Proteins, 16, 21, 25, 26, 43, 75, 76, 83
Argonaute, 60
Dicer, 70, 71
Drosha, 70
protein structure, 21
U2AF, 26
Publishing, 2, 5, 14, 16, 20, 21, 22, 23, 24,
25, 26, 30, 33, 36, 42, 43, 44, 45, 46, 47,
48, 49, 50, 52, 54, 56, 57, 58, 59, 60, 64,
65, 69, 70, 71, 72, 73, 74, 82, 84, 99, 100,
101, 102, 107, 114, 115, 117
Puerto Vallarta, Mexico, 51

R

Rabbis, 9, 10
Reed, Robin, 25
Regulus Therapeutics, 83
Republican Party, 2
Respiratory Syncytial Virus, 77
RNA, 20, 26, 30, 35, 44, 45, 46, 49, 74
let-7, 84
microRNA, 70, 83, 84, 85, 100, 101
miR-122, 84
mRNA, 25, 101
RNAi, 42, 43, 44, 45, 70, 85, 99, 102,
111
siRNA, 51, 77, 82, 102
snRNA, 25
Rockefeller University, 18, 19, 20, 21
Romney, Mitt [Willard Mitt], 112, 113
Roswell Park Cancer Institute, 7

S

Sandhamn, Sweden, 97
Schimmel, Paul R., 77
Schwarz, Dianne C., 106
Science, 54
Scientific American, 20
Scotland, 38

Scripps Research Institute, 32
Scriptgen, 31, 81
Searle Scholars Program, 51
Sharp, Phillip A., 30, 31, 43, 46, 47, 48, 74,
77
Skidmore College, 5
Skinner, B. F.[Burrhus Frederic], 6
Skirball Institute of Bimolecular Medicine,
30
State University of New York, Buffalo, 7
State University of New York, Stony Brook,
19
Steitz, Joan A., 26
Stem Cells, 116
Stockholm, Sweden, 97, 98
Stossel, Thomas P., 17
Strickland, Sid, 19
Sweden, 97
Switzerland, 7

T

Tenure, 26, 29, 30, 32, 40, 115, 118
Texas, 62
Texas A&M, 39, 41
The Boston Globe, 9
The Economist, 58
The New York Times, 9
The New Yorker, 58
The Republican War on Science, 105
Theurkauf, William E., 41
Tokyo, Japan, 113, 114
Triosephosphate Isomerase, 21
Tunicamycin, 7, 8
Tuschl, Thomas, 17, 32, 43, 44, 45, 46, 77

U

University and Small Business Patent
Procedures Act of 1980, 86

University of Massachusetts, Worcester, 26
Gretchen Stone Cook Professor of
Biomedical Sciences, 29
Medical School, 39, 42, 45, 50, 118
University of Pennsylvania, 21

V

Van Gogh, Vincent, 87
Venture Capitalists, 80
Vermont, 91

W

W. M. Keck Foundation, 63, 65
Wang, James C., 29
Washington D.C., 97
Washington University in St. Louis, 96
Water for Elephants, 87
Watson, James D., 72
Weinberg, Robert A., 44
Weissmann, Charles, 7
Whitehead Institute for Biomedical
Research, 27, 30, 31, 32, 39, 40
Williamson, James R., 31, 32, 33, 34, 35,
37, 40, 41, 50, 55
Worcester, Massachusetts, 93, 95
World War I, 55
World War II, 103, 104

Y

Young, Michael W., 19

Z

Zamore, Hannah, 92